367-30-6Relevant articles and documents
Co-MOF-Derived Hierarchical Mesoporous Yolk-shell-structured Nanoreactor for the Catalytic Reduction of Nitroarenes with Hydrazine Hydrate
Yuan, Man,Zhang, Hongbo,Yang, Chen,Wang, Fanhao,Dong, Zhengping
, p. 3327 - 3338 (2019)
Porous nanoreactors demonstrate immense potential for applications in heterogeneous catalysis due to their excellent mass-transfer performance and stability. The design of a simple, universal strategy for fabricating nanoreactor catalysts is of significance for organic transformation. In this study, a nanoreactor with a hierarchical mesoporous yolk-shell structure was successfully prepared by the high-temperature carbonization of a ZIF-67@polymer composite. The core of the resultant Co@ZDC@mC material comprised Co NPs anchored in the ZIF-67-derived carbon framework, while the shell comprised resin-polymer-derived mesoporous carbon. The as-obtained Co@ZDC@mC-700 catalyst enriched reactants, efficiently catalyzed the reaction in the core, and permitted the desorption of the product from the nanoreactor. In the catalytic reduction of nitrobenzene with N2H4?H2O, Co@ZDC@mC-700 exhibited superior catalytic efficiency (TOF=1136.3 h?1). In addition, Co@ZDC@mC-700 exhibited excellent performance for the catalytic reduction of various functionalized nitroarenes, as well as good reusability and recyclability. Hence, a simple, useful approach for fabricating a metal-organic-framework-derived non-noble metal-based yolk-shell nanoreactor for effective catalytic transformation is proposed.
Anion ligand promoted selective C-F bond reductive elimination enables C(sp2)-H fluorination
Mao, Yang-Jie,Luo, Gen,Hao, Hong-Yan,Xu, Zhen-Yuan,Lou, Shao-Jie,Xu, Dan-Qian
, p. 14458 - 14461 (2019/12/09)
A detailed mechanism study on the anion ligand promoted selective C-H bond fluorination is reported. The role of the anion ligand has been clarified by experimental evidence and DFT calculations. Moreover, the nitrate promoted C-F bond reductive elimination enabled a selective C-H bond fluorination of various symmetric and asymmetric azobenzenes to access diverse o-fluoroanilines.
NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS
-
Paragraph 0485; 0486, (2014/09/30)
This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, Von Hippel-Lindau Syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased RET kinase activity.
